Cytek Biosciences, Inc. (CTKB) Stock Analysis
Healthcare · Medical Devices · NasdaqGS
Cytek Biosciences, Inc. (CTKB) posted $201.49M in revenue for fiscal 2025 (up 0.5% year over year), with a net loss of $66.54M, and has compounded revenue about 209.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Cytek Biosciences, Inc.
Cytek Biosciences, Inc. has grown revenue from $710,000 to $201.49M over the last 6 fiscal years, compounding about 209.5% a year. The most recent year was up 0.5%, so growth has cooled from its longer-run pace.
Net margin sits at -33%, down 30 points year over year on a 51.8% gross margin.
The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Cytek Biosciences, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Cytek Biosciences, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $710,000 | $2.18M | $164.04M | $193.39M | $200.45M | $201.49M |
| Gross profit | $51.71M | $79.14M | $100.97M | $109.43M | $111.11M | $104.46M |
| Net income | $19.41M | $3.03M | $2.58M | $-11.33M | $-6.02M | $-66.54M |
| Net margin | 2733.9% | 138.8% | 1.6% | -5.9% | -3.0% | -33.0% |
Source: Cytek Biosciences, Inc. SEC filings (10-K).
Cytek Biosciences, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -33.0%).
Explore 6 years of Cytek Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CTKB in your portfolio →
Cytek Biosciences, Inc. financial history by metric
Compare Cytek Biosciences, Inc. with peers
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Cytek Biosciences, Inc. — frequently asked questions
What is Cytek Biosciences, Inc.'s revenue?
Cytek Biosciences, Inc. (CTKB) reported revenue of $201.49M for fiscal year 2025, up 0.5% from the prior year, according to its SEC filings.
Is Cytek Biosciences, Inc. profitable?
No — CTKB reported a net loss of $-66.54M in fiscal 2025.
What is CTKB's P/E ratio?
Cytek Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Cytek Biosciences, Inc. growing?
CTKB's revenue grew at roughly 209.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Cytek Biosciences, Inc. have?
As of fiscal year 2025, CTKB carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Cytek Biosciences, Inc.'s gross margin?
CTKB's gross margin was 51.8% in fiscal 2025 — gross profit of $104.46M on revenue of $201.49M.
What is Cytek Biosciences, Inc.'s market cap?
Cytek Biosciences, Inc. (CTKB) has a market capitalization of about $523.03M, based on the latest data in our nightly-refreshed cache.
When does Cytek Biosciences, Inc.'s fiscal year end?
CTKB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Cytek Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.